EASL Clinical Practice Guidelines


[1] Janssen, H.L., Garcia-Pagan, J.C., Elias, E., Mentha, G., Hadengue, A., and Valla, D.C. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003; 38: 364–371
Abstract | Full Text | Full Text PDF | PubMed | Scopus (247)

[2] Darwish, M.S., Plessier, A., Hernandez-Guerra, M., Fabris, F., Eapen, C.E., Bahr, M.J. et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009; 151: 167–175
CrossRef | PubMed

[3]Plessier, A., Darwish, M.S., Hernandez-Guerra, M., Consigny, Y., Fabris, F., Trebicka, J. et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010; 51: 210–218
CrossRef | PubMed | Scopus (138)

[4]Denninger, M.H., Chait, Y., Casadevall, N., Hillaire, S., Guillin, M.C., Bezeaud, A. et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000; 31: 587–591
CrossRef | PubMed

[5]Valla, D., Casadevall, N., Huisse, M.G., Tulliez, M., Grange, J.D., Muller, O. et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988; 94: 1063–1069

[6]Mohanty, D., Shetty, S., Ghosh, K., Pawar, A., and Abraham, P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology. 2001; 34: 666–670
CrossRef | PubMed | Scopus (88)

[7]Uskudar, O., Akdogan, M., Sasmaz, N., Yilmaz, S., Tola, M., and Sahin, B. Etiology and portal vein thrombosis in Budd-Chiari syndrome. World J Gastroenterol. 2008; 14: 2858–2862
CrossRef | PubMed | Scopus (28)

[8]El-Karaksy, H. and El-Raziky, M. Splanchnic vein thrombosis in the mediterranean area in children. Mediterr J Hematol Infect Dis. 2011; 3: e2011027
CrossRef | PubMed

[9]Middeldorp, S. and van Hylckama Vlieg, A. Does thrombophilia testing help in the clinical management of patients?. Br J Haematol. 2008; 143: 321–335
CrossRef | PubMed | Scopus (81)

[10]Janssen, H.L., Meinardi, J.R., Vleggaar, F.P., van Uum, S.H., Haagsma, E.B., Der Meer, F.J. et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000; 96: 2364–2368

[11]Smalberg, J.H., Darwish, M.S., Braakman, E., Valk, P.J., Janssen, H.L., and Leebeek, F.W. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica. 2006; 91: 1712–1713

[12]Primignani, M., Martinelli, I., Bucciarelli, P., Battaglioli, T., Reati, R., Fabris, F. et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005; 41: 603–608
CrossRef | PubMed | Scopus (135)

[13]Leebeek, F.W., Lameris, J.S., van Buuren, H.R., Gomez, E., Madretsma, S., and Sonneveld, P. Budd-Chiari syndrome, portal vein and mesenteric vein thrombosis in a patient homozygous for factor V Leiden mutation treated by TIPS and thrombolysis. Br J Haematol. 1998; 102: 929–931
CrossRef | PubMed | Scopus (40)

[14]Smalberg, J.H., Kruip, M.J., Janssen, H.L., Rijken, D.C., Leebeek, F.W., and de Maat, M.P. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol. 2011; 31: 485–493
CrossRef | PubMed | Scopus (19)

[15]Dentali, F., Galli, M., Gianni, M., and Ageno, W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost. 2008; 99: 675–682

[16]Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4: 295–306
CrossRef | PubMed | Scopus (2402)

[17]Martinelli, I., Primignani, M., Aghemo, A., Reati, R., Bucciarelli, P., Fabris, F. et al. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol. 2009; 50: 916–922
Abstract | Full Text | Full Text PDF | PubMed | Scopus (35)

[18]Raffa, S., Reverter, J.C., Seijo, S., Tassies, D., Abraldes, J.G., Bosch, J. et al. Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis. Clin Gastroenterol Hepatol. 2012; 10: 72–78
Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)

[19]Marchetti, M., Castoldi, E., Spronk, H.M., van Oerle, R., Balducci, D., Barbui, T. et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008; 112: 4061–4068
CrossRef | PubMed | Scopus (69)

[20]Tripodi, A., Primignani, M., Lemma, L., Chantarangkul, V., and Mannucci, P.M. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol. 2013; 59: 265–270
Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)

[21]Kiladjian, J.J., Cervantes, F., Leebeek, F.W., Marzac, C., Cassinat, B., Chevret, S. et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008; 111: 4922–4929
CrossRef | PubMed | Scopus (160)

[22]Colaizzo, D., Amitrano, L., Tiscia, G.L., Grandone, E., Guardascione, M.A., and Margaglione, M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood. 2007; 110: 2768–2769
CrossRef | PubMed | Scopus (26)

[23]Chait, Y., Condat, B., Cazals-Hatem, D., Rufat, P., Atmani, S., Chaoui, D. et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005; 129: 553–560
CrossRef | PubMed | Scopus (101)

[24]Smalberg, J.H., Arends, L.R., Valla, D.C., Kiladjian, J.J., Janssen, H.L., and Leebeek, F.W. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012; 120: 4921–4928
CrossRef | PubMed | Scopus (64)

[25]Janssen, H.L. and Leebeek, F.W. JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?. Hepatology. 2006; 44: 1391–1393
CrossRef | PubMed | Scopus (18)

[26]Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H., and Jaffe, E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117: 5019–5032
CrossRef | PubMed | Scopus (370)

[27]Klampfl, T., Gisslinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milosevic, J.D. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369: 2379–2390
CrossRef | PubMed | Scopus (271)

[28]Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369: 2391–2405
CrossRef | PubMed | Scopus (270)

[29]Turon, F., Cervantes, F., Colomer, D., Baiges, A., Hernandez-Gea, V., and Garcia-Pagan, J.C. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. J Hepatol. 2015; 62: 72–74
Abstract | Full Text | Full Text PDF | PubMed | Scopus (7)

[30]Plompen, E.P., Valk, P.J., Chu, I., Darwish, M.S., Plessier, A., Turon, F. et al. Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. Haematologica. 2015; 100: e226–e228
CrossRef | PubMed

[31]Landolfi, R., Di, G.L., and Falanga, A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008; 22: 2020–2028
CrossRef | PubMed | Scopus (77)

[32]Ziakas, P.D., Poulou, L.S., Rokas, G.I., Bartzoudis, D., and Voulgarelis, M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost. 2007; 5: 642–645
CrossRef | PubMed | Scopus (49)

[33]Hoekstra, J., Leebeek, F.W., Plessier, A., Raffa, S., Murad, S.D., Heller, J. et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol. 2009; 54: 908–914

[34]Brodsky, R.A. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008; 148: 587–595
CrossRef | PubMed

[35]van Bijnen, S.T., van Rijn, R.S., Koljenovic, S., te Boekhorst, P., de Witte, T., and Muus, P. Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab. Br J Haematol. 2012; 157: 762–763
CrossRef | PubMed | Scopus (3)

[36]Bayraktar, Y., Balkanci, F., Bayraktar, M., and Calguneri, M. Budd-Chiari syndrome: a common complication of Behcet’s disease. Am J Gastroenterol. 1997; 92: 858–862

[37]Justo, D., Finn, T., Atzmony, L., Guy, N., and Steinvil, A. Thrombosis associated with acute cytomegalovirus infection: a meta-analysis. Eur J Intern Med. 2011; 22: 195–199
Abstract | Full Text | Full Text PDF | PubMed | Scopus (26)

[38]Kochhar, R., Masoodi, I., Dutta, U., Singhal, M., Miglani, A., Singh, P. et al. Celiac disease and Budd Chiari syndrome: report of a case with review of literature. Eur J Gastroenterol Hepatol. 2009; 21: 1092–1094
CrossRef | PubMed | Scopus (9)

[39]Valla, D., Le, M.G., Poynard, T., Zucman, N., Rueff, B., and Benhamou, J.P. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology. 1986; 90: 807–811

[40]Amitrano, L., Guardascione, M.A., Scaglione, M., Pezzullo, L., Sangiuliano, N., Armellino, M.F. et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007; 102: 2464–2470
CrossRef | PubMed | Scopus (117)

[41]Spaander, M.C., Hoekstra, J., Hansen, B.E., van Buuren, H.R., Leebeek, F.W., and Janssen, H.L. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013; 11: 452–459
CrossRef | PubMed | Scopus (6)

[42]Condat, B., Pessione, F., Hillaire, S., Denninger, M.H., Guillin, M.C., Poliquin, M. et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001; 120: 490–497
Abstract | Full Text | Full Text PDF | PubMed

[43]Plessier, A., Rautou, P.E., and Valla, D.C. Management of hepatic vascular diseases. J Hepatol. 2012; 56: S25–S38
Abstract | Full Text PDF | PubMed | Scopus (55)

[44]Tait, C., Baglin, T., Watson, H., Laffan, M., Makris, M., Perry, D. et al. Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol. 2012; 159: 28–38
CrossRef | PubMed | Scopus (22)

[45]Baglin, T., Gray, E., Greaves, M., Hunt, B.J., Keeling, D., Machin, S. et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010; 149: 209–220
CrossRef | PubMed | Scopus (154)

[46]Hoekstra, J., Bresser, E.L., Smalberg, J.H., Spaander, M.C., Leebeek, F.W., and Janssen, H.L. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost. 2011; 9: 2208–2214
CrossRef | PubMed | Scopus (25)

[47]Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D. et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013; 368: 22–33
CrossRef | PubMed | Scopus (103)

[48]Plessier, A. and Valla, D.C. Budd-Chiari syndrome. Semin Liver Dis. 2008; 28: 259–269
CrossRef | PubMed | Scopus (53)

[49]Hernandez-Guerra, M., Turnes, J., Rubinstein, P., Olliff, S., Elias, E., Bosch, J. et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology. 2004; 40: 1197–1202
CrossRef | PubMed | Scopus (79)

[50]Darwish, M.S., Valla, D.C., de Groen, P.C., Zeitoun, G., Haagsma, E.B., Kuipers, E.J. et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol. 2006; 101: 83–90
CrossRef | PubMed | Scopus (37)

[51]Moucari, R., Rautou, P.E., Cazals-Hatem, D., Geara, A., Bureau, C., Consigny, Y. et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut. 2008; 57: 828–835
CrossRef | PubMed | Scopus (56)

[52]Plessier, A., Sibert, A., Consigny, Y., Hakime, A., Zappa, M., Denninger, M.H. et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology. 2006; 44: 1308–1316
CrossRef | PubMed | Scopus (111)

[53]Seijo, S., Plessier, A., Hoekstra, J., Dell’Era, A., Mandair, D., Rifai, K. et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013; 57: 1962–1968
CrossRef | PubMed | Scopus (34)

[54]DeLeve, L.D., Valla, D.C., and Garcia-Tsao, G. Vascular disorders of the liver. Hepatology. 2009; 49: 1729–1764
CrossRef | PubMed | Scopus (259)

[55]Rautou, P.E., Douarin, L., Denninger, M.H., Escolano, S., Lebrec, D., Moreau, R. et al. Bleeding in patients with Budd-Chiari syndrome. J Hepatol. 2011; 54: 56–63
Abstract | Full Text | Full Text PDF | PubMed | Scopus (11)

[56]Chagneau-Derrode C, Roy L, guilhot J, gloria O, Ollivier-Hourmand I, Bureau C, et al. Impact of cytoreductive therapy on the outcome of patients with myeloproliferative neoplasms and hepatosplanchnic vein thrombosis., 58 ed 2013. p. 857A.[57]Sharma, S., Texeira, A., Texeira, P., Elias, E., Wilde, J., and Olliff, S.P. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol. 2004; 40: 172–180
Abstract | Full Text | Full Text PDF | PubMed | Scopus (56)

[58]Smalberg, J.H., Spaander, M.V., Jie, K.S., Pattynama, P.M., van Buuren, H.R., van den, B.B. et al. Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis. Thromb Haemost. 2008; 100: 1084–1088

[59]Valla, D., Hadengue, A., El Younsi, M., Azar, N., Zeitoun, G., Boudet, M.J. et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology. 1997; 25: 814–819
CrossRef | PubMed | Scopus (54)

[60]Han, G., Qi, X., Zhang, W., He, C., Yin, Z., Wang, J. et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology. 2013; 266: 657–667
CrossRef | PubMed | Scopus (13)

[61]Tilanus, H.W. Budd-Chiari syndrome. Br J Surg. 1995; 82: 1023–1030
CrossRef | PubMed | Scopus (44)

[62]Zeitoun, G., Escolano, S., Hadengue, A., Azar, N., El Younsi, M., Mallet, A. et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999; 30: 84–89
CrossRef | PubMed | Scopus (148)

[63]Langlet, P. and Valla, D. Is surgical portosystemic shunt the treatment of choice in Budd-Chiari syndrome?. Acta Gastroenterol Belg. 2002; 65: 155–160

[64]Panis, Y., Belghiti, J., Valla, D., Benhamou, J.P., and Fekete, F. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery. 1994; 115: 276–281

[65]Bachet, J.B., Condat, B., Hagege, H., Plessier, A., Consigny, Y., Belghiti, J. et al. Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. J Hepatol. 2007; 46: 60–68
Abstract | Full Text | Full Text PDF | PubMed | Scopus (28)

[66]Hemming, A.W., Langer, B., Greig, P., Taylor, B.R., Adams, R., and Heathcote, E.J. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg. 1996; 171: 176–180
Abstract | Full Text PDF | PubMed | Scopus (90)

[67]Garcia-Pagan, J.C., Heydtmann, M., Raffa, S., Plessier, A., Murad, S., Fabris, F. et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008; 135: 808–815
Abstract | Full Text | Full Text PDF | PubMed | Scopus (124)

[68]Mentha, G., Giostra, E., Majno, P.E., Bechstein, W.O., Neuhaus, P., O’Grady, J. et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol. 2006; 44: 520–528
Abstract | Full Text | Full Text PDF | PubMed | Scopus (104)

[69]Segev, D.L., Nguyen, G.C., Locke, J.E., Simpkins, C.E., Montgomery, R.A., Maley, W.R. et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl. 2007; 13: 1285–1294
CrossRef | PubMed | Scopus (44)

[70]Rautou, P.E., Angermayr, B., Garcia-Pagan, J.C., Moucari, R., Peck-Radosavljevic, M., Raffa, S. et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. J Hepatol. 2009; 51: 47–54
Abstract | Full Text | Full Text PDF | PubMed | Scopus (21)

[71]Perarnau, J.M. and Bacq, Y. Hepatic vascular involvement related to pregnancy, oral contraceptives, and estrogen replacement therapy. Semin Liver Dis. 2008; 28: 315–327
CrossRef | PubMed | Scopus (16)

[72]Bates, S.M., Greer, I.A., Pabinger, I., Sofaer, S., and Hirsh, J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 844S–886S
CrossRef | PubMed | Scopus (472)

[73]Murad, S.D., Valla, D.C., de Groen, P.C., Zeitoun, G., Hopmans, J.A., Haagsma, E.B. et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004; 39: 500–508
CrossRef | PubMed | Scopus (164)

[74]Rautou, P.E., Moucari, R., Escolano, S., Cazals-Hatem, D., Denie, C., Chagneau-Derrode, C. et al. Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management. Am J Gastroenterol. 2009; 104: 1140–1146
CrossRef | PubMed | Scopus (15)

[75]de Franchis, R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010; 53: 762–768
Abstract | Full Text | Full Text PDF | PubMed | Scopus (496)

[76]Rajani, R., Bjornsson, E., Bergquist, A., Danielsson, A., Gustavsson, A., Grip, O. et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther. 2010; 32: 1154–1162
CrossRef | PubMed | Scopus (27)

[77]Turnes, J., Garcia-Pagan, J.C., Gonzalez, M., Aracil, C., Calleja, J.L., Ripoll, C. et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol. 2008; 6: 1412–1417
Abstract | Full Text | Full Text PDF | PubMed | Scopus (52)

[78]Condat, B., Pessione, F., Helene, D.M., Hillaire, S., and Valla, D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology. 2000; 32: 466–470
CrossRef | PubMed

[79]Acosta, S., Alhadad, A., Svensson, P., and Ekberg, O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg. 2008; 95: 1245–1251
CrossRef | PubMed | Scopus (85)

[80]Clavien, P.A., Durig, M., and Harder, F. Venous mesenteric infarction: a particular entity. Br J Surg. 1988; 75: 252–255
CrossRef | PubMed

[81]Clavien, P.A. and Harder, F. Mesenteric venous thrombosis. An 18-year retrospective study. Helv Chir Acta. 1988; 55: 29–34

[82]Kumar, S., Sarr, M.G., and Kamath, P.S. Mesenteric venous thrombosis. N Engl J Med. 2001; 345: 1683–1688
CrossRef | PubMed | Scopus (278)

[83]Hall, T.C., Garcea, G., Metcalfe, M., Bilku, D., and Dennison, A.R. Management of acute non-cirrhotic and non-malignant portal vein thrombosis: a systematic review. World J Surg. 2011; 35: 2510–2520
CrossRef | PubMed | Scopus (26)

[84]Elkrief, L., Corcos, O., Bruno, O., Larroque, B., Rautou, P.E., Zekrini, K. et al. Type 2 diabetes mellitus as a risk factor for intestinal resection in patients with superior mesenteric vein thrombosis. Liver Int. 2014; 34: 1314–1321
CrossRef | PubMed

[85]Senzolo, M., Riggio, O., and Primignani, M. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis. 2011; 43: 503–514
Abstract | Full Text | Full Text PDF | PubMed | Scopus (16)

[86]Berzigotti, A., Garcia-Criado, A., Darnell, A., and Garcia-Pagan, J.C. Imaging in clinical decision-making for portal vein thrombosis. Nat Rev Gastroenterol Hepatol. 2014; 11: 308–316
CrossRef | PubMed | Scopus (4)

[87]Ferri, P.M., Rodrigues, F.A., Fagundes, E.D., Xavier, S.G., Dias, R.D., Fernandes, A.P. et al. Evaluation of the presence of hereditary and acquired thrombophilias in Brazilian children and adolescents with diagnoses of portal vein thrombosis. J Pediatr Gastroenterol Nutr. 2012; 55: 599–604
CrossRef | PubMed | Scopus (2)

[88]Randi, M.L., Tezza, F., Scapin, M., Duner, E., Scarparo, P., Scandellari, R. et al. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis. Acta Haematol. 2010; 123: 140–145
CrossRef | PubMed | Scopus (6)

[89]Ferro, C., Rossi, U.G., Bovio, G., Dahamane, M., and Centanaro, M. Transjugular intrahepatic portosystemic shunt, mechanical aspiration thrombectomy, and direct thrombolysis in the treatment of acute portal and superior mesenteric vein thrombosis. Cardiovasc Intervent Radiol. 2007; 30: 1070–1074
CrossRef | PubMed | Scopus (24)

[90]Hollingshead, M., Burke, C.T., Mauro, M.A., Weeks, S.M., Dixon, R.G., and Jaques, P.F. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol. 2005; 16: 651–661
Abstract | Full Text | Full Text PDF | PubMed | Scopus (116)

[91]Liu, F.Y., Wang, M.Q., Duan, F., Wang, Z.J., and Song, P. Interventional therapy for symptomatic-benign portal vein occlusion. Hepatogastroenterology. 2010; 57: 1367–1374

[92]Wang, M.Q., Liu, F.Y., Duan, F., Wang, Z.J., Song, P., and Fan, Q.S. Acute symptomatic mesenteric venous thrombosis: treatment by catheter-directed thrombolysis with transjugular intrahepatic route. Abdom Imaging. 2011; 36: 390–398
CrossRef | PubMed | Scopus (10)

[93]Malkowski, P., Pawlak, J., Michalowicz, B., Szczerban, J., Wroblewski, T., Leowska, E. et al. Thrombolytic treatment of portal thrombosis. Hepatogastroenterology. 2003; 50: 2098–2100

[94]Cao, G., Ko, G.Y., Sung, K.B., Yoon, H.K., Gwon, D., and Kim, J.H. Treatment of postoperative main portal vein and superior mesenteric vein thrombosis with balloon angioplasty and/or stent placement. Acta Radiol. 2013; 54: 526–532
CrossRef | PubMed | Scopus (2)

[95]Condat, B. and Valla, D. Non malignant portal vein thrombosis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 505–515
CrossRef | PubMed | Scopus (68)

[96]Chirinos, J.A., Garcia, J., Alcaide, M.L., Toledo, G., Baracco, G.J., and Lichtstein, D.M. Septic thrombophlebitis: diagnosis and management. Am J Cardiovasc Drugs. 2006; 6: 9–14
CrossRef | PubMed | Scopus (30)

[97]Llop, E., de Juan, C., Seijo, S., Garcia-Criado, A., Abraldes, J.G., Bosch, J. et al. Portal cholangiopathy: radiological classification and natural history. Gut. 2011; 60: 853–860
CrossRef | PubMed | Scopus (20)

[98]Abd El-Hamid, N., Taylor, R.M., Marinello, D., Mufti, G.J., Patel, R., Mieli-Vergani, G. et al. Aetiology and management of extrahepatic portal vein obstruction in children: King’s College Hospital experience. J Pediatr Gastroenterol Nutr. 2008; 47: 630–634
CrossRef | PubMed | Scopus (31)

[99]Orr, D.W., Harrison, P.M., Devlin, J., Karani, J.B., Kane, P.A., Heaton, N.D. et al. Chronic mesenteric venous thrombosis: evaluation and determinants of survival during long-term follow-up. Clin Gastroenterol Hepatol. 2007; 5: 80–86
Abstract | Full Text | Full Text PDF | PubMed | Scopus (34)

[100]Dhiman, R.K., Behera, A., Chawla, Y.K., Dilawari, J.B., and Suri, S. Portal hypertensive biliopathy. Gut. 2007; 56: 1001–1008
CrossRef | PubMed | Scopus (73)

[101]Rangari, M., Gupta, R., Jain, M., Malhotra, V., and Sarin, S.K. Hepatic dysfunction in patients with extrahepatic portal venous obstruction. Liver Int. 2003; 23: 434–439
CrossRef | PubMed

[102]Minguez, B., Garcia-Pagan, J.C., Bosch, J., Turnes, J., Alonso, J., Rovira, A. et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology. 2006; 43: 707–714
CrossRef | PubMed | Scopus (69)

[103]Lautz, T.B., Sundaram, S.S., Whitington, P.F., Keys, L., and Superina, R.A. Growth impairment in children with extrahepatic portal vein obstruction is improved by mesenterico-left portal vein bypass. J Pediatr Surg. 2009; 44: 2067–2070
Abstract | Full Text | Full Text PDF | PubMed | Scopus (17)

[104]Marin, D., Galluzzo, A., Plessier, A., Brancatelli, G., Valla, D., and Vilgrain, V. Focal nodular hyperplasia-like lesions in patients with cavernous transformation of the portal vein: prevalence, MR findings and natural history. Eur Radiol. 2011; 21: 2074–2082
CrossRef | PubMed | Scopus (8)

[105]Bradbury, M.S., Kavanagh, P.V., Chen, M.Y., Weber, T.M., and Bechtold, R.E. Noninvasive assessment of portomesenteric venous thrombosis: current concepts and imaging strategies. J Comput Assist Tomogr. 2002; 26: 392–404
CrossRef | PubMed | Scopus (36)

[106]Ueno, N., Sasaki, A., Tomiyama, T., Tano, S., and Kimura, K. Color Doppler ultrasonography in the diagnosis of cavernous transformation of the portal vein. J Clin Ultrasound. 1997; 25: 227–233
CrossRef | PubMed | Scopus (46)

[107]Vilgrain, V., Condat, B., Bureau, C., Hakime, A., Plessier, A., Cazals-Hatem, D. et al. Atrophy-hypertrophy complex in patients with cavernous transformation of the portal vein: CT evaluation. Radiology. 2006; 241: 149–155
CrossRef | PubMed | Scopus (24)

[108]Seijo, S., Reverter, E., Miquel, R., Berzigotti, A., Abraldes, J.G., Bosch, J. et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis. 2012; 44: 855–860
Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)

[109]Koshy, A., Girod, C., Lee, S.S., Hadengue, A., Cerini, R., and Lebrec, D. Discrepancy between portal pressure and systemic hemodynamic changes after incremental doses of propranolol in awake portal hypertensive rats. Hepatology. 1989; 9: 269–273
CrossRef | PubMed

[110]Braillon, A., Moreau, R., Hadengue, A., Roulot, D., Sayegh, R., and Lebrec, D. Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol. J Hepatol. 1989; 9: 312–318
Abstract | Full Text PDF | PubMed

[111]Zargar, S.A., Javid, G., Khan, B.A., Yattoo, G.N., Shah, A.H., Gulzar, G.M. et al. Endoscopic ligation compared with sclerotherapy for bleeding esophageal varices in children with extrahepatic portal venous obstruction. Hepatology. 2002; 36: 666–672
CrossRef | PubMed | Scopus (99)

[112]Sarin, S.K., Gupta, N., Jha, S.K., Agrawal, A., Mishra, S.R., Sharma, B.C. et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology. 2010; 139: 1238–1245
Abstract | Full Text | Full Text PDF | PubMed | Scopus (23)

[113]Orloff, M.J., Orloff, M.S., Girard, B., and Orloff, S.L. Bleeding esophagogastric varices from extrahepatic portal hypertension: 40 years’ experience with portal-systemic shunt. J Am Coll Surg. 2002; 194: 717–728
Abstract | Full Text | Full Text PDF | PubMed | Scopus (81)

[114]Fanelli, F., Angeloni, S., Salvatori, F.M., Marzano, C., Boatta, E., Merli, M. et al. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis. 2011; 43: 78–84
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)

[115]Mack, C.L., Zelko, F.A., Lokar, J., Superina, R., Alonso, E.M., Blei, A.T. et al. Surgically restoring portal blood flow to the liver in children with primary extrahepatic portal vein thrombosis improves fluid neurocognitive ability. Pediatrics. 2006; 117: e405–e412
CrossRef | PubMed | Scopus (50)

[116]Superina, R.A. and Alonso, E.M. Medical and surgical management of portal hypertension in children. Curr Treat Options Gastroenterol. 2006; 9: 432–443
CrossRef | PubMed | Scopus (13)

[117]Senzolo, M., Tibbals, J., Cholongitas, E., Triantos, C.K., Burroughs, A.K., and Patch, D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther. 2006; 23: 767–775
CrossRef | PubMed | Scopus (94)

[118]Schouten, J.N., Garcia-Pagan, J.C., Valla, D.C., and Janssen, H.L. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011; 54: 1071–1081
CrossRef | PubMed | Scopus (54)

[119]Nakanuma, Y., Hoso, M., Sasaki, M., Terada, T., Katayanagi, K., Nonomura, A. et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology. 1996; 28: 195–204
CrossRef | PubMed

[120]Hillaire, S., Bonte, E., Denninger, M.H., Casadevall, N., Cadranel, J.F., Lebrec, D. et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002; 51: 275–280
CrossRef | PubMed | Scopus (135)

[121]Schouten, J.N., Nevens, F., Hansen, B., Laleman, W., van den, B.M., Komuta, M. et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther. 2012; 35: 1424–1433
CrossRef | PubMed | Scopus (13)

[122]Dhiman, R.K., Chawla, Y., Vasishta, R.K., Kakkar, N., Dilawari, J.B., Trehan, M.S. et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol. 2002; 17: 6–16
CrossRef | PubMed | Scopus (73)

[123]Krasinskas, A.M., Eghtesad, B., Kamath, P.S., Demetris, A.J., and Abraham, S.C. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005; 11: 627–634
CrossRef | PubMed | Scopus (78)

[124]Chang, P.E., Miquel, R., Blanco, J.L., Laguno, M., Bruguera, M., Abraldes, J.G. et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol. 2009; 104: 1707–1714
CrossRef | PubMed | Scopus (35)

[125]Seijo, S., Lozano, J.J., Alonso, C., Reverter, E., Miquel, R., Abraldes, J.G. et al. Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension. Am J Gastroenterol. 2013; 108: 926–932
CrossRef | PubMed | Scopus (4)

[126]Ibarrola, C. and Colina, F. Clinicopathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inadequate. Histopathology. 2003; 42: 251–264
CrossRef | PubMed | Scopus (48)

[127]Verheij, J., Schouten, J.N., Komuta, M., Nevens, F., Hansen, B.E., Janssen, H.L. et al. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. Histopathology. 2013; 62: 1083–1091
CrossRef | PubMed | Scopus (4)

[128]Wanless, I.R. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990; 11: 787–797
CrossRef | PubMed | Scopus (326)

[129]Siramolpiwat, S., Seijo, S., Miquel, R., Berzigotti, A., Garcia-Criado, A., Darnell, A. et al. Idiopathic portal hypertension: Natural history and long-term outcome. Hepatology. 2014; 59: 2276–2285
CrossRef | PubMed | Scopus (5)

[130]Chawla, Y.K., Dilawari, J.B., Dhiman, R.K., Goenka, M.K., Bhasin, D.K., Kochhar, R. et al. Sclerotherapy in noncirrhotic portal fibrosis. Dig Dis Sci. 1997; 42: 1449–1453
CrossRef | PubMed | Scopus (15)

[131]Bhargava, D.K., Dasarathy, S., Sundaram, K.R., and Ahuja, R.K. Efficacy of endoscopic sclerotherapy on long-term management of oesophageal varices: a comparative study of results in patients with cirrhosis of the liver, non-cirrhotic portal fibrosis (NCPF) and extrahepatic portal venous obstruction (EHO). J Gastroenterol Hepatol. 1991; 6: 471–475
CrossRef | PubMed

[132]Schiano, T.D., Kotler, D.P., Ferran, E., and Fiel, M.I. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol. 2007; 102: 2536–2540
CrossRef | PubMed | Scopus (72)

[133]Govani, F.S. and Shovlin, C.L. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet. 2009; 17: 860–871
CrossRef | PubMed | Scopus (151)

[134]Shovlin, C.L., Guttmacher, A.E., Buscarini, E., Faughnan, M.E., Hyland, R.H., Westermann, C.J. et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000; 91: 66–67
CrossRef | PubMed | Scopus (715)

[135]Buscarini, E., Leandro, G., Conte, D., Danesino, C., Daina, E., Manfredi, G. et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci. 2011; 56: 2166–2178
CrossRef | PubMed | Scopus (18)

[136]Memeo, M., Stabile Ianora, A.A., Scardapane, A., Suppressa, P., Cirulli, A., Sabba, C. et al. Hereditary haemorrhagic telangiectasia: study of hepatic vascular alterations with multi-detector row helical CT and reconstruction programs. Radiol Med. 2005; 109: 125–138

[137]Lesca, G., Olivieri, C., Burnichon, N., Pagella, F., Carette, M.F., Gilbert-Dussardier, B. et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med. 2007; 9: 14–22
CrossRef | PubMed | Scopus (70)

[138]Letteboer, T.G., Mager, H.J., Snijder, R.J., Lindhout, D., Ploos van Amstel, H.K., Zanen, P. et al. Genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A. 2008; 146A: 2733–2739
CrossRef | PubMed | Scopus (10)

[139]Buscarini, E., Danesino, C., Olivieri, C., Lupinacci, G., De, G.F., Reduzzi, L. et al. Doppler ultrasonographic grading of hepatic vascular malformations in hereditary hemorrhagic telangiectasia – results of extensive screening. Ultraschall Med. 2004; 25: 348–355
CrossRef | PubMed | Scopus (47)

[140]Garcia-Tsao, G., Korzenik, J.R., Young, L., Henderson, K.J., Jain, D., Byrd, B. et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2000; 343: 931–936
CrossRef | PubMed | Scopus (215)

[141]Buscarini, E., Danesino, C., Plauchu, H., de Fazio, C., Olivieri, C., Brambilla, G. et al. High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol. 2004; 30: 1089–1097
Abstract | Full Text | Full Text PDF | PubMed | Scopus (52)

[142]Buscarini, E., Plauchu, H., Garcia, T.G., White, R.I. Jr., Sabba, C., Miller, F. et al. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int. 2006; 26: 1040–1046
CrossRef | PubMed | Scopus (79)

[143]Faughnan, M.E., Palda, V.A., Garcia-Tsao, G., Geisthoff, U.W., McDonald, J., Proctor, D.D. et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011; 48: 73–87
CrossRef | PubMed | Scopus (193)

[144]Lerut, J., Orlando, G., Adam, R., Sabba, C., Pfitzmann, R., Klempnauer, J. et al. Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European liver transplant registry. Ann Surg. 2006; 244: 854–862
CrossRef | PubMed | Scopus (69)

[145]Dupuis-Girod, S., Chesnais, A.L., Ginon, I., Dumortier, J., Saurin, J.C., Finet, G. et al. Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study. Liver Transpl. 2010; 16: 340–347

[146]Buonamico, P., Suppressa, P., Lenato, G.M., Pasculli, G., D’Ovidio, F., Memeo, M. et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs. multislice computed tomography study. J Hepatol. 2008; 48: 811–820
Abstract | Full Text | Full Text PDF | PubMed | Scopus (29)

[147]Buscarini, E., Gebel, M., Ocran, K., Manfredi, G., Del Vecchio, B.G., Stefanov, R. et al. Interobserver agreement in diagnosing liver involvement in hereditary hemorrhagic telangiectasia by Doppler ultrasound. Ultrasound Med Biol. 2008; 34: 718–725
Abstract | Full Text | Full Text PDF | PubMed | Scopus (8)

[148]Gincul, R., Lesca, G., Gelas-Dore, B., Rollin, N., Barthelet, M., Dupuis-Girod, S. et al. Evaluation of previously nonscreened hereditary hemorrhagic telangiectasia patients shows frequent liver involvement and early cardiac consequences. Hepatology. 2008; 48: 1570–1576
CrossRef | PubMed | Scopus (15)

[149]Chavan, A., Luthe, L., Gebel, M., Barg-Hock, H., Seifert, H., Raab, R. et al. Complications and clinical outcome of hepatic artery embolisation in patients with hereditary haemorrhagic telangiectasia. Eur Radiol. 2013; 23: 951–957
CrossRef | PubMed | Scopus (2)

[150]Dupuis-Girod, S., Ginon, I., Saurin, J.C., Marion, D., Guillot, E., Decullier, E. et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012; 307: 948–955
CrossRef | PubMed | Scopus (53)

[151]Rubbia-Brandt, L. Sinusoidal obstruction syndrome. Clin Liver Dis. 2010; 14: 651–668
Abstract | Full Text | Full Text PDF | PubMed | Scopus (19)

[152]DeLeve, L.D., McCuskey, R.S., Wang, X., Hu, L., McCuskey, M.K., Epstein, R.B. et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 1999; 29: 1779–1791
CrossRef | PubMed | Scopus (141)

[153]McDonald, G.B., Slattery, J.T., Bouvier, M.E., Ren, S., Batchelder, A.L., Kalhorn, T.F. et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003; 101: 2043–2048
CrossRef | PubMed | Scopus (183)

[154]Coppell, J.A., Richardson, P.G., Soiffer, R., Martin, P.L., Kernan, N.A., Chen, A. et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010; 16: 157–168
Abstract | Full Text | Full Text PDF | PubMed | Scopus (71)

[155]Angliviel, B., Benoist, S., Penna, C., El, H.M., Chagnon, S., Julie, C. et al. Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol. 2009; 16: 1247–1253
CrossRef | PubMed | Scopus (23)

[156]Aloia, T., Sebagh, M., Plasse, M., Karam, V., Levi, F., Giacchetti, S. et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006; 24: 4983–4990
CrossRef | PubMed | Scopus (293)

[157]Nakano, H., Oussoultzoglou, E., Rosso, E., Casnedi, S., Chenard-Neu, M.P., Dufour, P. et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008; 247: 118–124
CrossRef | PubMed | Scopus (204)

[158]Chun, Y.S., Laurent, A., Maru, D., and Vauthey, J.N. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009; 10: 278–286
Abstract | Full Text | Full Text PDF | PubMed | Scopus (69)

[159]Mentha, G., Majno, P., Terraz, S., Rubbia-Brandt, L., Gervaz, P., Andres, A. et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol. 2007; 33: S76–S83
Abstract | Full Text | Full Text PDF | PubMed | Scopus (48)

[160]Overman, M.J., Maru, D.M., Charnsangavej, C., Loyer, E.M., Wang, H., Pathak, P. et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010; 28: 2549–2555
CrossRef | PubMed | Scopus (58)

[161]Soubrane, O., Brouquet, A., Zalinski, S., Terris, B., Brezault, C., Mallet, V. et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010; 251: 454–460
CrossRef | PubMed | Scopus (61)

[162]Slade, J.H., Alattar, M.L., Fogelman, D.R., Overman, M.J., Agarwal, A., Maru, D.M. et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009; 8: 225–230
Abstract | Full Text PDF | PubMed | Scopus (37)

[163]Miura, K., Nakano, H., Sakurai, J., Kobayashi, S., Koizumi, S., Arai, T. et al. Splenomegaly in FOLFOX-naive stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol. 2011; 16: 257–263
CrossRef | PubMed | Scopus (8)

[164]Angitapalli, R., Litwin, A.M., Kumar, P.R., Nasser, E., Lombardo, J., Mashtare, T. et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology. 2009; 76: 363–368
CrossRef | PubMed | Scopus (21)

[165]Mahgerefteh, S.Y., Sosna, J., Bogot, N., Shapira, M.Y., Pappo, O., and Bloom, A.I. Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. Radiology. 2011; 258: 660–671
CrossRef | PubMed | Scopus (16)

[166]Ward, J., Guthrie, J.A., Sheridan, M.B., Boyes, S., Smith, J.T., Wilson, D. et al. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol. 2008; 26: 4304–4310
CrossRef | PubMed | Scopus (36)

[167]O’Rourke, T.R., Welsh, F.K., Tekkis, P.P., Lyle, N., Mustajab, A., John, T.G. et al. Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol. 2009; 35: 1085–1091
Abstract | Full Text | Full Text PDF | PubMed | Scopus (14)

[168]Shin, N.Y., Kim, M.J., Lim, J.S., Park, M.S., Chung, Y.E., Choi, J.Y. et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol. 2012; 22: 864–871
CrossRef | PubMed | Scopus (17)

[169]Shulman, H.M., Fisher, L.B., Schoch, H.G., Henne, K.W., and McDonald, G.B. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology. 1994; 19: 1171–1181
CrossRef | PubMed

[170]Carreras, E., Granena, A., Navasa, M., Bruguera, M., Marco, V., Sierra, J. et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol. 1993; 66: 77–80
CrossRef | PubMed | Scopus (57)

[171]Rubbia-Brandt, L., Audard, V., Sartoretti, P., Roth, A.D., Brezault, C., Le, C.M. et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004; 15: 460–466
CrossRef | PubMed | Scopus (518)

[172]Rubbia-Brandt, L., Lauwers, G.Y., Wang, H., Majno, P.E., Tanabe, K., Zhu, A.X. et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010; 56: 430–439
CrossRef | PubMed | Scopus (104)

[173]Shulman, H.M., Gooley, T., Dudley, M.D., Kofler, T., Feldman, R., Dwyer, D. et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation. 1995; 59: 1015–1022
CrossRef | PubMed

[174]Esposito, A.A., Nicolini, A., Meregaglia, D., Sangiovanni, A., and Biondetti, P. Role of transjugular liver biopsy in the diagnostic and therapeutic management of patients with severe liver disease. Radiol Med. 2008; 113: 1008–1017
CrossRef | PubMed | Scopus (6)

[175]Brouquet, A., Benoist, S., Julie, C., Penna, C., Beauchet, A., Rougier, P. et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009; 145: 362–371
Abstract | Full Text | Full Text PDF | PubMed | Scopus (58)

[176]Goekkurt, E., Stoehlmacher, J., Stueber, C., Wolschke, C., Eiermann, T., Iacobelli, S. et al. Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. Anticancer Res. 2007; 27: 4377–4380

[177]Corbacioglu, S., Cesaro, S., Faraci, M., Valteau-Couanet, D., Gruhn, B., Rovelli, A. et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012; 379: 1301–1309
Abstract | Full Text | Full Text PDF | PubMed | Scopus (38)

[178]Imran, H., Tleyjeh, I.M., Zirakzadeh, A., Rodriguez, V., and Khan, S.P. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant. 2006; 37: 677–686
CrossRef | PubMed | Scopus (21)

[179]Richardson, P.G., Soiffer, R.J., Antin, J.H., Uno, H., Jin, Z., Kurtzberg, J. et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010; 16: 1005–1017
Abstract | Full Text | Full Text PDF | PubMed | Scopus (69)

[180]Northup, P.G., McMahon, M.M., Ruhl, A.P., Altschuler, S.E., Volk-Bednarz, A., Caldwell, S.H. et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol. 2006; 101: 1524–1528
CrossRef | PubMed | Scopus (141)

[181]Sogaard, K.K., Horvath-Puho, E., Gronbaek, H., Jepsen, P., Vilstrup, H., and Sorensen, H.T. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2009; 104: 96–101
CrossRef | PubMed | Scopus (137)

[182]Tripodi, A. and Mannucci, P.M. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365: 147–156
CrossRef | PubMed | Scopus (280)

[183]Rodriguez-Castro, K.I., Porte, R.J., Nadal, E., Germani, G., Burra, P., and Senzolo, M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation. 2012; 94: 1145–1153
CrossRef | PubMed | Scopus (27)

[184]Francoz, C., Belghiti, J., Vilgrain, V., Sommacale, D., Paradis, V., Condat, B. et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005; 54: 691–697
CrossRef | PubMed | Scopus (194)

[185]Zocco, M.A., Di, S.E., De, C.R., Novi, M., Ainora, M.E., Ponziani, F. et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009; 51: 682–689
Abstract | Full Text | Full Text PDF | PubMed | Scopus (120)

[186]Ogren, M., Bergqvist, D., Bjorck, M., Acosta, S., Eriksson, H., and Sternby, N.H. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006; 12: 2115–2119

[187]Amitrano, L., Guardascione, M.A., Scaglione, M., Menchise, A., Martino, R., Manguso, F. et al. Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2012; 24: 1381–1385
CrossRef | PubMed | Scopus (0)

[188]Augustin, S., Altamirano, J., Gonzalez, A., Dot, J., Abu-Suboh, M., Armengol, J.R. et al. Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding. Am J Gastroenterol. 2011; 106: 1787–1795
CrossRef | PubMed | Scopus (24)

[189]D’Amico, G. and de Franchis, R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003; 38: 599–612
CrossRef | PubMed | Scopus (385)

[190]Amitrano, L., Guardascione, M.A., Brancaccio, V., Margaglione, M., Manguso, F., Iannaccone, L. et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004; 40: 736–741
Abstract | Full Text | Full Text PDF | PubMed | Scopus (224)

[191]Englesbe, M.J., Kubus, J., Muhammad, W., Sonnenday, C.J., Welling, T., Punch, J.D. et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl. 2010; 16: 83–90
CrossRef | PubMed | Scopus (69)

[192]Amitrano, L., Brancaccio, V., Guardascione, M.A., Margaglione, M., Sacco, M., Martino, R. et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy. 2002; 34: 535–538
CrossRef | PubMed | Scopus (46)

[193]Erkan, O., Bozdayi, A.M., Disibeyaz, S., Oguz, D., Ozcan, M., Bahar, K. et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol. 2005; 17: 339–343
CrossRef | PubMed | Scopus (43)

[194]Tublin, M.E., Dodd, G.D. III, and Baron, R.L. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol. 1997; 168: 719–723
CrossRef | PubMed

[195]Rossi, S., Rosa, L., Ravetta, V., Cascina, A., Quaretti, P., Azzaretti, A. et al. Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. AJR Am J Roentgenol. 2006; 186: 763–773
CrossRef | PubMed | Scopus (58)

[196]Villa, E., Camma, C., Marietta, M., Luongo, M., Critelli, R., Colopi, S. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012; 143: 1253–1260
Abstract | Full Text | Full Text PDF | PubMed | Scopus (105)

[197]Luca, A., Caruso, S., Milazzo, M., Marrone, G., Mamone, G., Crino, F. et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012; 265: 124–132
CrossRef | PubMed | Scopus (28)

[198]Nery, F., Chevret, S., Condat, B., De, R.E., Boudaoud, L., Rautou, P.E. et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015; 61: 660–667
CrossRef | PubMed

[199]Senzolo, M., Sartori, M., Rossetto, V., Burra, P., Cillo, U., Boccagni, P. et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012; 32: 919–927
CrossRef | PubMed | Scopus (65)

[200]Amitrano, L., Guardascione, M.A., Menchise, A., Martino, R., Scaglione, M., Giovine, S. et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010; 44: 448–451

[201]Delgado, M.G., Seijo, S., Yepes, I., Achecar, L., Catalina, M.V., Garcia-Criado, A. et al. Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis1. Clin Gastroenterol Hepatol. 2012; 10: 776–783
Abstract | Full Text | Full Text PDF | PubMed | Scopus (68)

[202]Werner, K.T., Sando, S., Carey, E.J., Vargas, H.E., Byrne, T.J., Douglas, D.D. et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013; 58: 1776–1780
CrossRef | PubMed | Scopus (18)

[203]Luca, A., Miraglia, R., Caruso, S., Milazzo, M., Sapere, C., Maruzzelli, L. et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut. 2011; 60: 846–852
CrossRef | PubMed | Scopus (62)

[204]Perarnau, J.M., Baju, A., d’Alteroche, L., Viguier, J., and Ayoub, J. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis. Eur J Gastroenterol Hepatol. 2010; 22: 1093–1098
CrossRef | PubMed | Scopus (33)

[205]Han, G., Qi, X., He, C., Yin, Z., Wang, J., Xia, J. et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 2011; 54: 78–88
Abstract | Full Text | Full Text PDF | PubMed | Scopus (71)

[206]Senzolo, M., Patch, D., Burra, P., and Burroughs, A.K. Tips for portal vein thrombosis (PVT) in cirrhosis: not only unblocking a pipe. J Hepatol. 2011; 55: 945–946
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)

[207]Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., Goldhaber, S.Z. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e419S–e494S
CrossRef | PubMed | Scopus (1000)

[208]Garcia, D.A., Baglin, T.P., Weitz, J.I., and Samama, M.M. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e24S–e43S
CrossRef | PubMed | Scopus (202)

[209]Rodriguez-Castro, K.I., Simioni, P., Burra, P., and Senzolo, M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int. 2012; 32: 1465–1476
CrossRef | PubMed | Scopus (20)

[210]Bechmann, L.P., Wichert, M., Kroger, K., and Hilgard, P. Dosing and monitoring of low-molecular-weight heparin in cirrhotic patients. Liver Int. 2011; 31: 1064
CrossRef | PubMed | Scopus (6)

[211]Lisman, T. and Porte, R.J. Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver Int. 2011; 31: 1063
CrossRef | PubMed | Scopus (19)

[212]Senzolo, M., Rodriguez-Castro, K.I., Rossetto, V., Radu, C., Gavasso, S., Carraro, P. et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost. 2012; 10: 1823–1829
CrossRef | PubMed | Scopus (20)

[213]Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M., and Palareti, G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e44S–e88S
CrossRef | PubMed | Scopus (393)

[214]van den Besselaar, A.M., Barrowcliffe, T.W., Houbouyan-Reveillard, L.L., Jespersen, J., Johnston, M., Poller, L. et al. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost. 2004; 2: 1946–1953
CrossRef | PubMed | Scopus (60)

[215]Tripodi, A., Chantarangkul, V., and Mannucci, P.M. The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. J Thromb Haemost. 2008; 6: 243–248
CrossRef | PubMed

[216]Tripodi, A. and Palareti, G. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. J Intern Med. 2012; 271: 554–565
CrossRef | PubMed | Scopus (16)

[217]Liakoni, E., Ratz Bravo, A.E., Terracciano, L., Heim, M., and Krahenbuhl, S. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med. 2014; 174: 1683–1686
CrossRef | PubMed | Scopus (9)